Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

ALPN

Alpine Immune Sciences Inc

Apr 17 • 04:00PM ET

64.46

Dollar change -0.04
Percentage change -0.06	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IBB SCHA LABU IWO IWN DWAS PTH

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.69	Insider Own	28.22%	Shs Outstand	60.35M	Perf Week	37.03%
Market Cap	4.23B	Forward P/E	-	EPS next Y	-1.96	Insider Trans	-16.24%	Shs Float	47.05M	Perf Month	81.73%
Income	-32.18M	PEG	-	EPS next Q	-0.43	Inst Own	68.40%	Short Float	11.23%	Perf Quarter	217.07%
Sales	58.88M	P/S	71.76	EPS this Y	-174.80%	Inst Trans	37.61%	Short Ratio	2.55	Perf Half Y	544.60%
Book/sh	5.43	P/B	11.86	EPS next Y	-11.44%	ROA	-9.63%	Short Interest	5.28M	Perf Year	765.23%
Cash/sh	4.99	P/C	12.91	EPS next 5Y	-	ROE	-12.69%	52W Range	6.71 - 64.57	Perf YTD	238.20%
Dividend Est.	-	P/FCF	-	EPS past 5Y	24.56%	ROI	-9.55%	52W High	-0.17%	Beta	0.98
Dividend TTM	-	Quick Ratio	7.86	Sales past 5Y	171.70%	Gross Margin	99.02%	52W Low	860.66%	ATR (14)	3.15
Dividend Ex-Date	-	Current Ratio	7.86	EPS Y/Y TTM	58.73%	Oper. Margin	-75.16%	RSI (14)	83.50	Volatility	0.26% 7.08%
Employees	142	Debt/Eq	0.03	Sales Y/Y TTM	95.84%	Profit Margin	-54.66%	Recom	2.75	Target Price	65.00
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	124.03%	Payout	-	Rel Volume	1.27	Prev Close	64.50
Sales Surprise	238.91%	EPS Surprise	145.45%	Sales Q/Q	1011.42%	Earnings	Mar 18 AMC	Avg Volume	2.08M	Price	64.46
SMA20	45.77%	SMA50	71.54%	SMA200	219.84%	Trades		Volume	2,633,301	Change	-0.06%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-09-24	Initiated	Guggenheim	Buy	$55
Feb-15-24	Initiated	Wolfe Research	Outperform	$44
Oct-18-23	Initiated	Berenberg	Buy	$18
Oct-17-23	Initiated	Berenberg	Buy	$18
Oct-05-23	Initiated	RBC Capital Mkts	Outperform	$19
Jun-26-23	Resumed	Oppenheimer	Outperform	$14
Jan-19-23	Initiated	Morgan Stanley	Overweight	$17
Nov-21-22	Initiated	SVB Leerink	Outperform	$15
Dec-21-20	Initiated	H.C. Wainwright	Buy	$21
Aug-26-20	Initiated	Cowen	Outperform

Apr-15-24 09:15AM	Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock (Motley Fool)
Apr-13-24 05:29AM	Could This Stock Be the Next Biotech Buyout? (Motley Fool)
Apr-12-24 12:36PM	Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex (Zacks)
10:55AM	Health Care Roundup: Market Talk (The Wall Street Journal)
Apr-11-24 04:43PM	These Stocks Moved the Most Today: CarMax, Apple, Fastenal, Rivian, Alpine Immune, Nike, Robinhood, Constellation Brands, and More (Barrons.com) +36.90%
04:29PM	Loading…
04:29PM	Vertex Pharmaceuticals to buy Alpine Immune Sciences in $4.9B deal (Yahoo Finance Video)
04:18PM	Alpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy It (Investor's Business Daily)
01:59PM	Stocks to Watch Thursday: Robinhood, Alpine Immune, Constellation Brands (The Wall Street Journal)
01:07PM	These Stocks Are Moving the Most Today: CarMax, Fastenal, Rivian, Alpine Immune, Nike, Robinhood, Constellation Brands, and More (Barrons.com)
11:58AM	Top Stock Movers Now: Nike, Constellation Brands, Fastenal, and More (Investopedia)
11:03AM	Vertex Pharmaceuticals Seeks a Second Act With Alpine Immune Deal. What Wall Street Says. (Barrons.com)
09:47AM	These Stocks Are Moving the Most Today (Barrons.com)
09:47AM	The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today (InvestorPlace)
09:39AM	Vertex to Pay $4.9 Billion for Kidney Disease Drug Developer (Bloomberg)
07:34AM	5 Things to Know Before the Stock Market Opens (Investopedia)
10:34PM	Loading…
Apr-10-24 10:34PM	Vertex Stock in Focus After Deal to Buy Alpine Immune For $4.9B Key Level to Watch (Investopedia) +20.80%
07:05PM	Biotech giant Vertex bought Alpine in a cash deal of $4.9 billion (Quartz)
05:47PM	Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion (The Wall Street Journal)
05:14PM	Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal (Investor's Business Daily)
04:19PM	Vertex Pharma bets on kidney disease treatment with $4.9 billion Alpine Immune deal (Reuters)
04:16PM	UPDATE 3-Vertex Pharma bets on kidney disease treatment with $4.9 bln Alpine Immune deal (Reuters)
04:15PM	Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy (Business Wire)
04:06PM	Vertex to acquire Alpine Immune Sciences for $4.9 bln (Reuters)
04:01PM	Vertex Enters Into Agreement to Acquire Alpine Immune Sciences (Business Wire)
01:34PM	Vertex to buy kidney disease drugmaker Alpine for $4.9B (BioPharma Dive)
Apr-09-24 09:23AM	Alpine Immune Sciences (ALPN) Moves 10.4% Higher: Will This Strength Last? (Zacks)
Apr-01-24 09:00AM	Alpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024 (Business Wire)
Mar-21-24 07:45AM	Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024 (Business Wire)
Mar-20-24 04:30PM	Alpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference (Business Wire)
Mar-19-24 08:32AM	Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Q4 2023 Earnings Call Transcript (Insider Monkey) +12.63%
06:48AM	Loading…
06:48AM	Q4 2023 Alpine Immune Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-18-24 08:53PM	ALPN Stock Earnings: Alpine Immune Sciences Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
07:25PM	Alpine Immune Sciences, Inc. (ALPN) Q4 Earnings and Revenues Beat Estimates (Zacks)
05:31PM	Alpine Immune Sciences Inc (ALPN) Reports Full Year 2023 Financial Results (GuruFocus.com)
04:05PM	Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results (Business Wire)
Mar-14-24 08:38AM	Is a Surprise Coming for Alpine Immune Sciences (ALPN) This Earnings Season? (Zacks)
Mar-11-24 10:00AM	Alpine Immune Sciences, Inc. (ALPN) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Mar-07-24 04:30PM	Alpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-26-24 04:30PM	Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences (Business Wire)
Feb-01-24 04:30PM	Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences (Business Wire) +5.15%
Dec-21-23 04:15PM	Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie (Business Wire)
Dec-19-23 09:50AM	Is Alpine Immune Sciences (ALPN) Stock Outpacing Its Medical Peers This Year? (Zacks) +5.39%
Dec-18-23 04:30PM	Alpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-06-23 09:55AM	Wall Street Analysts See a 56.25% Upside in Alpine Immune Sciences, Inc. (ALPN): Can the Stock Really Move This High? (Zacks) +5.73%
Nov-29-23 09:40AM	Is Alpine Immune Sciences (ALPN) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-20-23 04:30PM	Alpine Immune Sciences to Participate in the Evercore ISI HealthconX Conference (Business Wire)
09:55AM	Wall Street Analysts Think Alpine Immune Sciences, Inc. (ALPN) Could Surge 79.37%: Read This Before Placing a Bet (Zacks)
Nov-17-23 07:44PM	Six Flags, Howard Hughes, and More Stocks See Action From Activist Investors (Barrons.com) +5.69%
Nov-15-23 09:00AM	Alpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023 (Business Wire) +5.60%
Nov-14-23 08:55PM	Alpine Immune Sciences Inc (ALPN) Reports Encouraging Q3 2023 Results; Advances Povetacicept ... (GuruFocus.com)
04:15PM	Alpine Immune Sciences Reports Third Quarter 2023 Financial Results (Business Wire)
03:57PM	Orbimed Advisors LLC Bolsters Portfolio with Alpine Immune Sciences Inc Stake (GuruFocus.com)
Nov-13-23 09:00AM	Alpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023 (Business Wire) -5.40%
Nov-06-23 09:41PM	Alpine Immune Sciences Announces Pricing of $150 Million Public Offering (Business Wire) -12.07%
06:00AM	Alpine Immune Sciences Announces Proposed Public Offering (Business Wire)
Nov-03-23 09:00AM	Alpine Immune Sciences Presents New Preclinical Data on Povetacicept in Myasthenia Gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine 2023 Annual Meeting (Business Wire) +9.17%
Nov-02-23 09:00AM	Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023 (Business Wire) +39.92%
Oct-30-23 10:01AM	Alpine Immune Sciences, Inc. (ALPN) Surges 8.9%: Is This an Indication of Further Gains? (Zacks) +5.16%
09:00AM	Alpine Immune Sciences to Present New Translational Data on Povetacicept and Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023 (Business Wire)
Oct-27-23 09:40AM	Are Medical Stocks Lagging Alcon (ALC) This Year? (Zacks) +8.90%
Oct-23-23 12:00PM	Alpine Immune Sciences, Inc. (ALPN) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks) -8.87%
Oct-13-23 09:05AM	Alpine Immune Sciences to Present Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late Breaker Poster Session at American Society of Nephrology Kidney Week 2023 (Business Wire) -6.13%
Oct-12-23 12:13PM	Lilly (LLY) Up on NVO's Ozempic Early Success in Kidney Study (Zacks)
Oct-11-23 10:15AM	Merck's (MRK) Keytruda Early-Stage NSCLC Study Shows OS Benefit (Zacks)
Oct-09-23 11:10AM	J&J (JNJ) Seeks EU Nod for Rybrevant for First-Line NSCLC (Zacks)
Oct-06-23 09:55AM	Wall Street Analysts Believe Alpine Immune Sciences, Inc. (ALPN) Could Rally 50.37%: Here's is How to Trade (Zacks)
09:24AM	AbbVie (ABBV) Buys Parkinson's Disease Treatment Maker (Zacks)
Oct-04-23 08:17AM	AstraZeneca (AZN) Settles Heartburn Drugs Lawsuits for $425M (Zacks)
08:00AM	Alpine Immune Sciences Announces Appointment of Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer and Grant under Nasdaq Listing Rule 5635(c) (Business Wire)
Oct-03-23 07:43AM	Lilly's (LLY) Eczema Candidate Lebrikizumab Faces FDA Rejection (Zacks)
Sep-18-23 08:52AM	5 Stocks to Buy as Drug Industry Displays Strong Fundamentals (Zacks)
Sep-12-23 08:30AM	Alpine Immune Sciences Presents First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting (Business Wire)
Sep-08-23 09:40AM	Has SiBone (SIBN) Outpaced Other Medical Stocks This Year? (Zacks)
Sep-05-23 04:30PM	Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences (Business Wire)
08:30AM	Alpine Immune Sciences to Present First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting (Business Wire)
Aug-30-23 04:30PM	Alpine Immune Sciences Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3) (Business Wire)
Aug-24-23 08:50AM	Alpine Immune Sciences, Inc. (ALPN) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Aug-22-23 04:30PM	Alpine Immune Sciences Announces Appointment of M. Christina Yi as Chief Technology Officer and Grant under Nasdaq Listing Rule 5635(c) (Business Wire)
Aug-17-23 09:55AM	Does Alpine Immune Sciences, Inc. (ALPN) Have the Potential to Rally 25.38% as Wall Street Analysts Expect? (Zacks)
Aug-14-23 04:15PM	Alpine Immune Sciences Reports Second Quarter 2023 Financial Results (Business Wire)
Jul-23-23 10:25AM	Alpine Immune Sciences, Inc. (NASDAQ:ALPN) surges 14%; private equity firms who own 38% shares profited along with institutions (Simply Wall St.)
Jun-22-23 07:43AM	Alpine Immune (ALPN) Stock Up 19% MTD, Will the Uptick Continue? (Zacks)
Jun-20-23 07:14PM	Alpine Immune Sciences, Inc. (ALPN) Soars 5.6%: Is Further Upside Left in the Stock? (Zacks) +5.59%
May-19-23 04:30PM	Alpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific Congresses (Business Wire) +10.47%
May-11-23 04:15PM	Alpine Immune Sciences Reports First Quarter 2023 Financial Results (Business Wire)
May-05-23 07:04AM	Pinning Down Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) P/S Is Difficult Right Now (Simply Wall St.) +8.04%
May-01-23 04:30PM	Alpine Immune Sciences Announces Participation in the Bank of America Securities Healthcare Conference (Business Wire)
Mar-27-23 09:16AM	Even though Alpine Immune Sciences (NASDAQ:ALPN) has lost US$39m market cap in last 7 days, shareholders are still up 200% over 3 years (Simply Wall St.) -6.04%
07:08AM	Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-24-23 10:02AM	Q4 2022 Alpine Immune Sciences Inc Earnings Call (Thomson Reuters StreetEvents) -8.25%
Mar-23-23 05:35PM	Alpine Immune Sciences, Inc. (ALPN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Mar-20-23 04:30PM	Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data and Clinical Pharmacokinetic & Pharmacodynamic Modeling at Upcoming Scientific Conferences (Business Wire) -5.01%
Mar-16-23 05:30PM	Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data at the 2023 American Academy of Dermatology Annual Meeting (Business Wire)
Mar-15-23 04:30PM	Alpine Immune Sciences to Report Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-28-23 04:33PM	Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences (Business Wire)
Feb-13-23 05:16AM	Alpine Immune Sciences, Inc. (NASDAQ:ALPN) most popular amongst private equity firms who own 38% of the shares, institutions hold 33% (Simply Wall St.)
Feb-09-23 04:45PM	Alpine Immune Sciences to Participate in the SVB Securities Global Biopharma Conference (Business Wire)
Jan-17-23 08:36AM	Are Options Traders Betting on a Big Move in Alpine (ALPN) Stock? (Zacks)
Nov-22-22 04:15PM	Alpine Immune Sciences Announces Participation in Fireside Chat at the 5th Annual Evercore ISI HealthCONx Conference (Business Wire)

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company, which focusses on discovering and developing innovative, protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies. The company was founded in March 2007 and is headquartered in Seattle, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rickey James Paul	See Remarks	Jan 26 '24	Option Exercise	8.30	117,764	977,844	73,764	Jan 29 07:04 PM
Rickey James Paul	See Remarks	Jan 26 '24	Sale	23.32	117,764	2,745,830	0	Jan 29 07:04 PM
Rickey James Paul	See Remarks	Jan 25 '24	Option Exercise	6.51	236	1,536	236	Jan 29 07:04 PM
Rickey James Paul	See Remarks	Jan 25 '24	Sale	22.00	236	5,192	0	Jan 29 07:04 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 28 '23	Option Exercise	12.74	74,441	948,378	2,675,421	Dec 29 07:32 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 28 '23	Option Exercise	0.65	1,016	660	1,016	Dec 29 07:32 PM
ORBIMED ADVISORS LLC	Director	Dec 28 '23	Sale	18.35	1,364,849	25,049,034	264,315	Dec 29 04:18 PM
Thompson Peter A.	Director	Dec 28 '23	Sale	18.35	1,364,849	25,049,034	264,315	Dec 29 04:20 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 28 '23	Sale	20.04	1,016	20,362	0	Dec 29 07:32 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 27 '23	Option Exercise	0.65	29,573	19,222	29,573	Dec 27 09:07 PM
ORBIMED ADVISORS LLC	Director	Dec 27 '23	Sale	19.96	181,498	3,622,700	406,609	Dec 29 04:18 PM
Thompson Peter A.	Director	Dec 27 '23	Sale	19.96	181,498	3,622,700	406,609	Dec 29 04:20 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 27 '23	Sale	20.04	29,573	592,717	0	Dec 27 09:07 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 26 '23	Option Exercise	0.63	24,486	15,436	24,486	Dec 27 09:07 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 26 '23	Sale	20.22	24,486	495,217	0	Dec 27 09:07 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 22 '23	Option Exercise	0.45	37,825	17,021	37,825	Dec 27 09:07 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 22 '23	Sale	20.43	37,825	772,595	0	Dec 27 09:07 PM
Rickey James Paul	See Remarks	Dec 19 '23	Option Exercise	5.02	15,213	76,369	15,213	Dec 21 07:35 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 19 '23	Option Exercise	0.45	2,402	1,081	2,402	Dec 21 07:34 PM
Rickey James Paul	See Remarks	Dec 19 '23	Sale	19.21	15,213	292,222	0	Dec 21 07:35 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 19 '23	Sale	20.01	2,402	48,064	0	Dec 21 07:34 PM
Rickey James Paul	See Remarks	Dec 18 '23	Option Exercise	5.02	1,800	9,036	1,800	Dec 18 09:20 PM
Rickey James Paul	See Remarks	Dec 18 '23	Sale	19.00	1,800	34,203	0	Dec 18 09:20 PM
Rickey James Paul	See Remarks	Dec 15 '23	Option Exercise	5.02	45,387	227,843	45,387	Dec 18 09:20 PM
Rickey James Paul	See Remarks	Dec 15 '23	Sale	19.09	45,387	866,383	0	Dec 18 09:20 PM
Rickey James Paul	See Remarks	Dec 14 '23	Option Exercise	5.02	11,600	58,232	11,600	Dec 18 09:20 PM
Rickey James Paul	See Remarks	Dec 14 '23	Sale	19.00	11,600	220,406	0	Dec 18 09:20 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 12 '23	Option Exercise	0.45	8,613	3,876	8,613	Dec 12 09:02 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 12 '23	Sale	17.32	41,063	711,026	0	Dec 12 09:02 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 11 '23	Sale	17.26	68,870	1,189,027	32,450	Dec 12 09:02 PM
GOLD MITCHELL	Executive Chairman and CEO	Dec 08 '23	Sale	17.08	8,067	137,784	101,320	Dec 12 09:02 PM
Rickey James Paul	See Remarks	Dec 06 '23	Option Exercise	3.23	6,446	20,821	6,446	Dec 06 07:31 PM
Rickey James Paul	See Remarks	Dec 06 '23	Sale	16.08	6,446	103,650	0	Dec 06 07:31 PM
Rickey James Paul	See Remarks	Dec 05 '23	Option Exercise	3.23	418	1,350	418	Dec 06 07:31 PM
Rickey James Paul	See Remarks	Dec 05 '23	Sale	16.01	418	6,694	0	Dec 06 07:31 PM
Rickey James Paul	See Remarks	Dec 04 '23	Option Exercise	3.23	63,947	206,549	63,947	Dec 06 07:31 PM
Rickey James Paul	See Remarks	Dec 04 '23	Sale	16.06	63,947	1,026,887	0	Dec 06 07:31 PM
Rickey James Paul	See Remarks	Nov 30 '23	Option Exercise	3.23	700	2,261	700	Dec 01 05:00 PM
Rickey James Paul	See Remarks	Nov 30 '23	Sale	16.00	700	11,200	0	Dec 01 05:00 PM
Rickey James Paul	See Remarks	Nov 06 '23	Option Exercise	3.23	10,989	35,494	18,003	Nov 08 05:20 PM
Rickey James Paul	See Remarks	Nov 06 '23	Sale	16.03	18,003	288,554	0	Nov 08 05:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALPN

Alpine Immune Sciences Inc

Upgrade your FINVIZ experience